Singapore markets open in 8 hours 54 minutes
Straits Times Index
3,255.54 +16.51 (+0.51%) S&P 500
3,972.37 -5.16 (-0.13%) Dow
32,488.04 +55.96 (+0.17%) Nasdaq
11,697.27 -71.57 (-0.61%) Bitcoin USD
26,989.36 +50.10 (+0.19%) CMC Crypto 200
591.46 +348.78 (+143.72%)
AZN Oct 2023 27.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 04:58PM EDT. Market open.
| Previous close | 41.30 |
| Open | 41.30 |
| Bid | 40.05 |
| Ask | 41.85 |
| Strike | 27.50 |
| Expiry date | 2023-10-20 |
| Day's range | 41.30 - 41.30 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
